Specify a stock or a cryptocurrency in the search bar to get a summary
Solasia Pharma KK
4597Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. The company was founded in 2006 and is based in Tokyo, Japan. Address: Sumitomo Fudosan Shiba-Koen Tower, Tokyo, Japan, 105-0011
Analytics
WallStreet Target Price
8 423.87 JPYP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 4597
Dividend Analytics 4597
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 4597
Stock Valuation 4597
Financials 4597
Results | 2019 | Dynamics |